DANIEL ULRICH: Open Payments
NPI 1508075698 · KIRKSVILLE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$375 in 25 payments from 9 companies in 2025. Trend: 2023 $612 · 2024 $330 · 2025 $375
Food & beverage: $375
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $170 |
| Janssen Pharmaceuticals, Inc | 3 | $53 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
Products named: VRAYLAR, INVEGA SUSTENNA, COBENFY, REXULTI, INGREZZA, CAPLYTA, AUSTEDO XR, Auvelity.
Industry payments across MO — which companies pay providers there.
